Literature DB >> 9631141

No evidence for proliferation in the blood CD4+ T-cell pool during HIV-1 infection and triple combination therapy.

O Tissot1, J P Viard, C Rabian, N Ngo, M Burgard, C Rouzioux, C Penit.   

Abstract

OBJECTIVE: To evaluate the role of cell proliferation in peripheral blood lymphocyte (PBL) dynamics during HIV infection and potent antiretroviral therapy including protease inhibitors.
DESIGN: Transverse study of 150 patients at different stages of infection. Longitudinal study of 50 patients on triple combination antiretroviral therapy with 9-month follow-up.
METHODS: Ex vivo incubation of fresh PBL with the DNA biosynthetic marker bromodeoxyuridine (BrdU). Flow cytometric analysis of cell phenotypes and BrdU incorporation. Parallel determination of plasma virus load and CD4+ cell counts.
RESULTS: Percentages of BrdU+ B and T lymphocytes found in patients with asymptomatic HIV infection were not different from the low values found in HIV-seronegative controls, and were not correlated with the CD4+ cell count. DNA synthesis increased significantly only during acute opportunistic infections occurring in patients with high plasma viral load and fewer than 100 x 10(6) CD4+ cells/l. Triple combination therapy induced a decrease of plasma virus load and a rise of CD4+ cell counts, whereas BrdU incorporation remained low or decreased.
CONCLUSION: Proliferation of peripheral blood T cells observed at late stages of HIV infection corresponds to a response to opportunistic infections. Apart from these particular cases, proliferation in this compartment does not appear as a critical parameter of CD4+ cell kinetics during chronic HIV infection and potent therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9631141     DOI: 10.1097/00002030-199808000-00010

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  6 in total

1.  Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients.

Authors:  P M Roger; J P Breittmayer; C Arlotto; P Pugliese; C Pradier; G Bernard-Pomier; P Dellamonica; A Bernard
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy.

Authors:  S Fleury; G P Rizzardi; A Chapuis; G Tambussi; C Knabenhans; E Simeoni; J Y Meuwly; J M Corpataux; A Lazzarin; F Miedema; G Pantaleo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

3.  Adrenaline-induced mobilization of T cells in HIV-infected patients.

Authors:  S R Søndergaard; A Cozzi Lepri; H Ullum; J Wiis; C K Hermann; S B Laursen; J Qvist; J Gerstoft; P Skinhøj; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

4.  Mortality and immunological recovery among older adults on antiretroviral therapy at a large urban HIV clinic in Kampala, Uganda.

Authors:  Aggrey S Semeere; Isaac Lwanga; Joseph Sempa; Sujal Parikh; Noeline Nakasujja; Robert Cumming; Andrew Kambugu; Harriet Mayanja-Kizza
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-01       Impact factor: 3.731

5.  Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy.

Authors:  Kadija Benlhassan-Chahour; Claude Penit; Vincent Dioszeghy; Florence Vasseur; Geneviève Janvier; Yves Rivière; Nathalie Dereuddre-Bosquet; Dominique Dormont; Roger Le Grand; Bruno Vaslin
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

6.  Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.

Authors:  J A Kovacs; R A Lempicki; I A Sidorov; J W Adelsberger; B Herpin; J A Metcalf; I Sereti; M A Polis; R T Davey; J Tavel; J Falloon; R Stevens; L Lambert; R Dewar; D J Schwartzentruber; M R Anver; M W Baseler; H Masur; D S Dimitrov; H C Lane
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.